Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.

BACKGROUND In patients receiving intracoronary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the procedure. However, ticlopidine causes neutropenia in 1% of patients when administered for >2 weeks, and little is known about the duration that ticlopidine needs be administered to prevent stent thrombosis. METHODS AND RESULTS We analyzed 827 patients undergoing successful stent placement in 1061 coronary segments at Mayo Clinic who were treated between May 1, 1996, and October 31, 1997. Chronic warfarin therapy, cardiogenic shock, and enrollment in research protocols requiring 4 weeks of ticlopidine were exclusion criteria; ticlopidine was discontinued after 14 days in all remaining patients. The mean age of the study population was 64+/-11 years; 49% had suffered a prior infarction, 20% had undergone coronary artery bypass surgery, and 65% had multivessel disease. The indication for stent placement was dissection or abrupt closure in 31% of patients and suboptimal results from balloon angioplasty in 18%. Placement was elective in 51% of patients, and 10.3% of patients were treated within 12 hours of an acute myocardial infarction. Mean nominal stent size was 3.3+/-0.5 mm. High-pressure inflations (>/=12 atm) were performed in all patients (mean, 17+/-4 atm). Intravascular ultrasound was used to facilitate stent placement in 8.8% of patients. Abciximab was administered to 38% of patients; 11% of patients who were at increased risk of stent thrombosis were treated with enoxaparin for 10 to 14 days. Adverse cardiovascular events in the 14 days after stent placement occurred in 11 patients (1.3%). Two patients died of nonischemic causes (sepsis and renal failure) in the 15th through 30th days after ticlopidine was stopped. However, there were no cardiovascular deaths, myocardial infarctions, coronary artery bypass operations, or repeat angioplasty procedures between the 15th and 30th days; stent thrombosis did not occur in any patient after ticlopidine had been stopped. No patient developed neutropenia, although 1.8% of the first 489 patients who were closely monitored for side effects from ticlopidine developed side effects requiring its discontinuation, and milder side effects occurred in 4.7%. CONCLUSIONS In patients receiving intracoronary stents, the discontinuation of ticlopidine therapy 14 days after stent placement is associated with a very low frequency of stent thrombosis and other adverse events.

[1]  K. Goa,et al.  Erratum to: Ticlopidine: a review of its pharmacology clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke , 1996, Drugs & aging.

[2]  G. Albers,et al.  Ticlopidine Review of its Pharmacology, Clinical Efficacy and Tolerability in the Prevention of Cerebral Ischaemia and Stroke , 1996 .

[3]  A. Kastrati,et al.  A RANDOMIZED COMPARISON OF ANTIPLATELET THERAPY AFTER THE PLACEMENT OF CORONARY ARTERY STENTS , 1996 .

[4]  P Hall,et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. , 1995, Circulation.

[5]  K. Schrör Antiplatelet drugs. A comparative review. , 1995, Drugs.

[6]  I. Penn,et al.  Thrombosis and restenosis after stenting in failed angioplasty: comparison with elective stenting. , 1994, American heart journal.

[7]  E. Topol,et al.  Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group. , 1994, Circulation.

[8]  J. Hirshfeld,et al.  Comparison of results of intracoronary stenting in patients with unstable vs. stable angina. , 1994, Catheterization and Cardiovascular Diagnosis.

[9]  K. Kodama,et al.  Neointimal coverage of stents in human coronary arteries observed by angioscopy. , 1994, Journal of the American College of Cardiology.

[10]  R. Erbel,et al.  Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. , 1993, American heart journal.

[11]  E. Topol,et al.  Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome. , 1993, Journal of the American College of Cardiology.

[12]  Ticlopidine versus aspirin for stroke prevention: On-treatment results from the ticlopidine aspirin stroke study. , 1993, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[13]  P. Bergeron,et al.  Long-term peripheral stent evaluation using angioscopy. , 1991, International angiology : a journal of the International Union of Angiology.

[14]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[15]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[16]  T. Ryan Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[17]  F. Loop,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.